| Symbol | LRMR |
|---|---|
| Name | LARIMAR THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | THREE BALA PLAZA EAST,SUITE 506, BALA CYNWYD, Pennsylvania, 19004, United States |
| Telephone | +1 844 511-9056 |
| Fax | — |
| — | |
| Website | https://www.larimartx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001374690 |
| Description | Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreichs ataxia. Additional info from NASDAQ: |
(99% Neutral) LARIMAR THERAPEUTICS, INC. (LRMR) Announces Regulatory Update
Read moreNew Form SCHEDULE 13G/A - Larimar Therapeutics, Inc. <b>Filed:</b> 2026-05-14 <b>AccNo:</b> 0001140361-26-021322 <b>Size:</b> 8 KB
Read more(30% Negative) LARIMAR THERAPEUTICS, INC. (LRMR) Reports Q2 2026 Financial Results
Read moreNew Form ARS - Larimar Therapeutics, Inc. <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001193125-26-163954 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Larimar Therapeutics, Inc. <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001193125-26-163942 <b>Size:</b> 13 MB
Read moreNew Form PRE 14A - Larimar Therapeutics, Inc. <b>Filed:</b> 2026-04-10 <b>AccNo:</b> 0001193125-26-151258 <b>Size:</b> 12 MB
Read moreNew Form S-8 - Larimar Therapeutics, Inc. <b>Filed:</b> 2026-03-19 <b>AccNo:</b> 0001193125-26-116159 <b>Size:</b> 175 KB
Read moreNew Form 10-K - Larimar Therapeutics, Inc. <b>Filed:</b> 2026-03-19 <b>AccNo:</b> 0001193125-26-115878 <b>Size:</b> 13 MB
Read more(30% Negative) LARIMAR THERAPEUTICS, INC. (LRMR) Reports Q1 2026 Financial Results
Read moreLarimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06681766 | A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ata… | Phase1 | Friedreich Ataxia | Terminated | 2024-12-06 | 2025-04-28 | ClinicalTrials.gov |
| NCT06447025 | An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia | Phase2 | Friedreich Ataxia | Recruiting | 2024-01-25 | 2027-01-01 | ClinicalTrials.gov |
| NCT05579691 | A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult… | Phase2 | Friedreich Ataxia | Completed | 2022-09-21 | 2023-12-04 | ClinicalTrials.gov |
| NCT05028764 | Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers | — | Friedreich Ataxia | Completed | 2021-08-04 | 2022-02-04 | ClinicalTrials.gov |
| NCT04519567 | Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Fried… | Phase1 | Friedreich Ataxia | Completed | 2020-07-31 | 2021-03-16 | ClinicalTrials.gov |
| NCT04255680 | A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia | — | Friedreich Ataxia | Completed | 2020-01-14 | 2020-06-30 | ClinicalTrials.gov |
| NCT04176991 | Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedre… | Phase1 | Friedreich Ataxia | Completed | 2019-12-11 | 2020-10-31 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |
| Buccal Swabs and Blood Draws | Other | Preclinical | Friedreich Ataxia | COMPLETED | NCT04255680 |
| Placebo | Other | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT04176991 |
| CTI-1601 | Other | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT04176991 |
| Placebo | Other | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT04519567 |
| CTI-1601 | Other | Phase PHASE1 | Friedreich Ataxia | COMPLETED | NCT04519567 |
| Buccal Swabs, Blood Draws and Skin Punch Biopsy | Other | Preclinical | Friedreich Ataxia | COMPLETED | NCT05028764 |
| Placebo | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT05579691 |
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | COMPLETED | NCT05579691 |
| Placebo | Other | Phase PHASE1 | Friedreich Ataxia | TERMINATED | NCT06681766 |
| Nomlabofusp | Other | Phase PHASE1 | Friedreich Ataxia | TERMINATED | NCT06681766 |
| CTI-1601 | Other | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |
| Nomlabofusp | DRUG | Phase PHASE1 | Friedreich Ataxia | TERMINATED | NCT06681766 |
| Placebo | DRUG | Phase PHASE1 | Friedreich Ataxia | TERMINATED | NCT06681766 |
| CTI-1601 | DRUG | Phase PHASE2 | Friedreich Ataxia | RECRUITING | NCT06447025 |